Philip Savage

Philip Savage is a lymphoma oncologist specializing in relapsed/refractory DLBCL and the development of CD20xCD3 bispecific T cell engagers. He contributed to the pivotal glofitamab trial in relapsed/refractory DLBCL demonstrating durable complete responses leading to FDA approval in 2023. His research addresses sequencing of bispecific antibodies and CAR-T in DLBCL, management of cytokine release syndrome, and emerging resistance mechanisms. He participates in NCI-Canada and ALLIANCE lymphoma studies and contributes to Canadian consensus guidelines for DLBCL management.